ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss - Pharmaceutical Technology

At ECO 2026, findings from the ATTAIN-MAINTAIN trial were presented, assessing (orforglipron) for maintaining body weight loss in obese or overweight adults. The trial enrolled participants who had completed the SURMOUNT-5 study and achieved at least 5% weight loss. The trial targets obese or overweight patients who had achieved notable weight loss on Wegovy (semaglutide) or Zepbound (tirzepatide). Credit: oleschwander / Shutterstock.com. On 13 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3b ATTAIN-MAINTAIN trial (NCT06584916) were presented, assessing Eli Lilly’s Foundayo (orforglipron) for the maintenance of body weight reduction in adults with…

Source: Pharmaceutical Technology